Patent · US Active

Compounds

US10023558B2 · kind B2 · utility

4Cited by
1References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 22, 2017
Grant dateJul 17, 2018
Priority date
Expiry dateSep 22, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D471/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.